167 related articles for article (PubMed ID: 30608614)
21. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.
Askanase A; Li X; Pong A; Shum K; Kamp S; Carthen F; Aberle T; Hanrahan L; Daly P; Giles J; Merrill JT
Lupus Sci Med; 2015; 2(1):e000075. PubMed ID: 25861457
[TBL] [Abstract][Full Text] [Related]
22. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
[TBL] [Abstract][Full Text] [Related]
23. Musculoskeletal manifestations of systemic lupus erythematosus.
Shumilova A; Vital EM
Best Pract Res Clin Rheumatol; 2023 Dec; 37(4):101859. PubMed ID: 37620235
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Burge DJ; Werth VP; Boackle SA; Posada J
Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
[TBL] [Abstract][Full Text] [Related]
25. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
[TBL] [Abstract][Full Text] [Related]
26. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.
Urowitz MB; Isenberg DA; Wallace DJ
Lupus Sci Med; 2015; 2(1):e000104. PubMed ID: 26301100
[TBL] [Abstract][Full Text] [Related]
28. Novel evidence-based systemic lupus erythematosus responder index.
Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
[TBL] [Abstract][Full Text] [Related]
29. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
van Vollenhoven RF; Stohl W; Furie RA; Fox NL; Groark JG; Bass D; Kurtinecz M; Pobiner BF; Eastman WJ; Gonzalez-Rivera T; Gordon D
Lupus Sci Med; 2018; 5(1):e000288. PubMed ID: 30588323
[TBL] [Abstract][Full Text] [Related]
30. Which outcome measures in SLE clinical trials best reflect medical judgment?
Thanou A; Chakravarty E; James JA; Merrill JT
Lupus Sci Med; 2014; 1(1):e000005. PubMed ID: 25396057
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.
Fatemi A; Raeisi A; Sayedbonakdar Z; Smiley A
Clin Rheumatol; 2018 Apr; 37(4):955-962. PubMed ID: 29256112
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
[TBL] [Abstract][Full Text] [Related]
33. What is the best instrument to measure disease activity in SLE? - SLE-DAS vs Easy BILAG.
Inês LS; Fredi M; Jesus D; Shumilova A; Franceschini F; Vital EM
Autoimmun Rev; 2024 Jan; 23(1):103428. PubMed ID: 37634675
[TBL] [Abstract][Full Text] [Related]
34. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
[TBL] [Abstract][Full Text] [Related]
35. Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study.
Abbasifard M; Khorramdelazad H; Rostamian A; Rezaian M; Askari PS; Sharifi GTK; Parizi MK; Sharifi MTK; Najafizadeh SR
Trials; 2023 Feb; 24(1):129. PubMed ID: 36810107
[TBL] [Abstract][Full Text] [Related]
36. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
Merrill JT; Furie R; Werth VP; Khamashta M; Drappa J; Wang L; Illei G; Tummala R
Lupus Sci Med; 2018; 5(1):e000284. PubMed ID: 30588322
[TBL] [Abstract][Full Text] [Related]
37. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
[TBL] [Abstract][Full Text] [Related]
39. [Feasibility of SLEDAI-2000 and BILAG-2004 scoring systems for assessing renal disease activity in children with lupus nephritis].
Zhou JQ; Jiang H
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):775-9. PubMed ID: 23092572
[TBL] [Abstract][Full Text] [Related]
40. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
